Table 1 Clinical characteristics of demyelinating diseases in Western Australia
Conventional MS (Total, n = 703)OSMS (n = 31)Acute myelitis (n = 50)ON CIS (N = 42)Primary progress (n = 53)
Female/male2.841.2*2.573.20.89**
Age at onset (SD) (years)35.93 (11.10)36.29 (11.25)40.21 (12.91)*35.85 (11.83)45.67 (10.97)**
Duration of disease (SD) (years)12.84 (9.12)12.29 (9.18)10.75 (10.82)11.21 (10.16)14.11 (7.5)
CSF examination
Cell counts (SD) (/µl)5.28 (19.39)41.44 (129.12)**4.72 (9.97)6.0 (10.20)2 (2.76)
Total protein (SD) (mg/dL)0.45 (0.39)0.59 (0.63)0.47 (0.20)0.4 (0.08)0.46 (0.15)
Oligoclonal bands (%)142/214 (66.4)5/17 (29.4)**5/23 (21.7)**1/7 (14.3) **14/19 (73.4)
VEP abnormal (%)195/273 (71.4)17/20 (85.0)5/19 (26.3)**28/28 (100)**20/24 (83.3)
Brain MRI
Abnormalities (%)590/613 (96.2)15/31 (48.4)**6/41 (14.6)**12/38 (31.6)**39/45 (86.7)**
Spinal MRI
Abnormalities (%)373/439 (85.0)25/27 (92.6)35/44 (79.5)028/33 (84.8)
LESCLs (%)15/439 (3.42)6/27 (22.2)**2/44 (4.55)01/33 (3.03)
  • Values were significant in comparison with conventional MS: *p<0.05; **p<0.01.

  • CSF, cerebrospinal fluid; LESCLs, longitudinally extensive spinal cord lesions; MRI, magnetic resonance imaging; MS, multiple sclerosis; ON CIS, optic neuritis clinically isolated syndromes; OSMS, optic-spinal multiple sclerosis; SD, standard deviation; VEP, visual evoked potential.